SMT201600311B - Inibitori di cdk - Google Patents
Inibitori di cdkInfo
- Publication number
- SMT201600311B SMT201600311B SM201600311T SM201600311T SMT201600311B SM T201600311 B SMT201600311 B SM T201600311B SM 201600311 T SM201600311 T SM 201600311T SM 201600311 T SM201600311 T SM 201600311T SM T201600311 B SMT201600311 B SM T201600311B
- Authority
- SM
- San Marino
- Prior art keywords
- cdk inhibitors
- cdk
- inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/20—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/499—Spiro-condensed pyrazines or piperazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US40649810P | 2010-10-25 | 2010-10-25 | |
| PCT/US2011/057749 WO2012061156A1 (en) | 2010-10-25 | 2011-10-25 | Cdk inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SMT201600311B true SMT201600311B (it) | 2016-11-10 |
Family
ID=46024778
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SM201600311T SMT201600311B (it) | 2010-10-25 | 2016-09-09 | Inibitori di cdk |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US8598197B2 (it) |
| EP (6) | EP3981770A1 (it) |
| JP (4) | JP5923509B2 (it) |
| KR (4) | KR20200137048A (it) |
| CN (5) | CN104045654A (it) |
| AU (5) | AU2011323739B2 (it) |
| BR (1) | BR112013010018B1 (it) |
| CA (2) | CA2961937C (it) |
| CY (1) | CY1118004T1 (it) |
| DK (1) | DK2632467T3 (it) |
| ES (1) | ES2592515T3 (it) |
| HK (2) | HK1197067A1 (it) |
| HR (1) | HRP20161092T1 (it) |
| HU (1) | HUE030714T2 (it) |
| IL (5) | IL225940A0 (it) |
| LT (1) | LT2632467T (it) |
| MX (4) | MX367795B (it) |
| PL (1) | PL2632467T3 (it) |
| PT (1) | PT2632467T (it) |
| RS (1) | RS55135B1 (it) |
| RU (1) | RU2621674C2 (it) |
| SG (2) | SG10201508715YA (it) |
| SI (1) | SI2632467T1 (it) |
| SM (1) | SMT201600311B (it) |
| WO (1) | WO2012061156A1 (it) |
Families Citing this family (100)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101386494B1 (ko) | 2005-05-10 | 2014-04-24 | 인사이트 코포레이션 | 인돌아민 2,3-디옥시게나제의 조절제 및 이의 사용방법 |
| KR101649548B1 (ko) | 2008-07-08 | 2016-08-19 | 인사이트 홀딩스 코포레이션 | 인돌아민 ２,３-디옥시게나아제의 억제제로서의 １,２,５-옥사디아졸 |
| CN102458443A (zh) | 2009-05-13 | 2012-05-16 | 北卡罗来纳大学查珀尔希尔分校 | 细胞周期蛋白依赖性激酶抑制剂及使用方法 |
| US8691830B2 (en) | 2010-10-25 | 2014-04-08 | G1 Therapeutics, Inc. | CDK inhibitors |
| JP2013545758A (ja) | 2010-11-17 | 2013-12-26 | ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル | 増殖性キナーゼｃｄｋ４及びｃｄｋ６の阻害による虚血からの腎組織の保護 |
| EP3216792B1 (en) | 2012-03-29 | 2020-05-27 | G1 Therapeutics, Inc. | Lactam kinase inhibitors |
| US10202392B2 (en) * | 2012-04-26 | 2019-02-12 | Francis Xavier Tavares | Synthesis of lactams |
| ME03300B (me) | 2012-06-13 | 2019-07-20 | Incyte Holdings Corp | Supsтituisana triciklična jedinjenja као inhibiтori fgfr |
| US9527857B2 (en) * | 2013-03-15 | 2016-12-27 | GI Therapeutics, Inc. | HSPC-sparing treatments for RB-positive abnormal cellular proliferation |
| WO2014144740A2 (en) * | 2013-03-15 | 2014-09-18 | G1 Therapeutics, Inc. | Highly active anti-neoplastic and anti-proliferative agents |
| WO2014144596A2 (en) * | 2013-03-15 | 2014-09-18 | G1 Therapeutics, Inc. | Transient protection of hematopoietic stem and progenitor cells against ionizing radiation |
| DK2986610T5 (en) | 2013-04-19 | 2018-12-10 | Incyte Holdings Corp | BICYCLIC HETEROCYCLES AS FGFR INHIBITORS |
| US20150297606A1 (en) | 2014-04-17 | 2015-10-22 | G1 Therapeutics, Inc. | Tricyclic Lactams for Use in the Protection of Hematopoietic Stem and Progenitor Cells Against Ionizing Radiation |
| WO2016040858A1 (en) * | 2014-09-12 | 2016-03-17 | G1 Therapeutics, Inc. | Combinations and dosing regimes to treat rb-positive tumors |
| WO2016040848A1 (en) | 2014-09-12 | 2016-03-17 | G1 Therapeutics, Inc. | Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors |
| WO2016126889A1 (en) * | 2015-02-03 | 2016-08-11 | G1 Therapeutics, Inc. | Cdk4/6 inhibitor dosage formulations for the protection of hematopoietic stem and progenitor cells during chemotherapy |
| EA038045B1 (ru) | 2015-02-20 | 2021-06-28 | Инсайт Корпорейшн | Бициклические гетероциклы в качестве ингибиторов fgfr |
| MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
| JP2019520379A (ja) | 2016-07-01 | 2019-07-18 | ジー１ セラピューティクス， インコーポレイテッド | ピリミジン系の抗増殖剤 |
| WO2018005533A1 (en) | 2016-07-01 | 2018-01-04 | G1 Therapeutics, Inc. | Antiproliferative pyrimidine-based compounds |
| WO2018005865A1 (en) | 2016-07-01 | 2018-01-04 | G1 Therapeutics, Inc. | Synthesis of n-(heteroaryl)-pyrrolo[3,2-d]pyrimidin-2-amines |
| WO2018005863A1 (en) * | 2016-07-01 | 2018-01-04 | G1 Therapeutics, Inc. | Pyrimidine-based compounds for the treatment of cancer |
| CN109803684B (zh) | 2016-08-23 | 2022-08-23 | 卫材 R&D 管理有限公司 | 用于治疗肝细胞癌的组合疗法 |
| EP3804724B1 (en) | 2016-10-20 | 2022-12-07 | Pfizer Inc. | Cdk inhibitors for treating pah |
| WO2018089518A1 (en) | 2016-11-08 | 2018-05-17 | Dana-Farber Cancer Institute, Inc. | Compositions and methods of modulating anti-tumor immunity |
| US11168088B2 (en) | 2016-11-11 | 2021-11-09 | Shanghai Haiyan Pharmaceutical Technology Co., Ltd. | Pyridylamino substituted heterotricyclic compounds, and preparation method and pharmaceutical use thereof |
| KR20240023677A (ko) | 2016-12-05 | 2024-02-22 | 쥐원 쎄라퓨틱스, 인크. | 화학요법 레지멘 동안의 면역 반응의 보존 |
| MX2019008158A (es) | 2017-01-06 | 2019-12-09 | G1 Therapeutics Inc | Terapia de combinacion para el tratamiento del cancer. |
| US11395821B2 (en) | 2017-01-30 | 2022-07-26 | G1 Therapeutics, Inc. | Treatment of EGFR-driven cancer with fewer side effects |
| CN110325191A (zh) | 2017-02-22 | 2019-10-11 | G1治疗公司 | 以较少的副作用治疗egfr-驱动的癌症 |
| JP7219224B2 (ja) | 2017-03-16 | 2023-02-07 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 乳癌の治療のための組合せ療法 |
| AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
| RU2019142591A (ru) * | 2017-06-29 | 2021-07-29 | Г1 Терапьютикс, Инк. | Морфологические формы g1t38 и способы их получения |
| CN107383019B (zh) * | 2017-07-28 | 2019-10-15 | 江苏艾凡生物医药有限公司 | 吡唑并[4,3-h]喹唑啉类化合物及其用途 |
| CN109985241A (zh) * | 2017-12-29 | 2019-07-09 | 广州威溶特医药科技有限公司 | Cdk抑制剂和溶瘤病毒在制备抗肿瘤药物的应用 |
| RU2020123665A (ru) | 2018-01-08 | 2022-02-10 | Г1 Терапьютикс, Инк. | Преимущественные режимы дозирования g1т38 |
| CN112384515A (zh) | 2018-02-27 | 2021-02-19 | 因赛特公司 | 作为a2a/a2b抑制剂的咪唑并嘧啶和***并嘧啶 |
| US11466004B2 (en) | 2018-05-04 | 2022-10-11 | Incyte Corporation | Solid forms of an FGFR inhibitor and processes for preparing the same |
| EA202092649A1 (ru) | 2018-05-04 | 2021-06-21 | Инсайт Корпорейшн | Соли ингибитора fgfr |
| MX2020012376A (es) | 2018-05-18 | 2021-03-09 | Incyte Corp | Derivados de pirimidina fusionados como inhibidores de los receptores de adenosina a2a/a2b. |
| EP3818063A1 (en) | 2018-07-05 | 2021-05-12 | Incyte Corporation | Fused pyrazine derivatives as a2a / a2b inhibitors |
| KR20210049847A (ko) | 2018-08-24 | 2021-05-06 | 쥐원 쎄라퓨틱스, 인크. | 1,4-디아자스피로[5.5]운데칸-3-온의 개선된 합성 |
| JP2022500388A (ja) | 2018-09-10 | 2022-01-04 | ミラティ セラピューティクス， インコーポレイテッド | 組み合わせ療法 |
| US11066404B2 (en) | 2018-10-11 | 2021-07-20 | Incyte Corporation | Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors |
| WO2020097625A1 (en) * | 2018-11-09 | 2020-05-14 | G1 Therapeutics, Inc. | Therapeutic regimens for treatment of cancer using eribulin and selective cdk4/6 inhibitor combinations |
| CN113195000A (zh) | 2018-12-21 | 2021-07-30 | 第一三共株式会社 | 抗体-药物缀合物和激酶抑制剂的组合 |
| CN111377924A (zh) * | 2018-12-29 | 2020-07-07 | 武汉光谷通用名药物研究院有限公司 | 新型cdk4抑制剂及其用途 |
| CN111377935B (zh) * | 2018-12-29 | 2021-06-29 | 武汉光谷通用名药物研究院有限公司 | 选择性cdk4/6抑制剂及其应用 |
| TWI829857B (zh) | 2019-01-29 | 2024-01-21 | 美商英塞特公司 | 作為a2a / a2b抑制劑之吡唑并吡啶及***并吡啶 |
| CA3130210A1 (en) | 2019-02-15 | 2020-08-20 | Incyte Corporation | Cyclin-dependent kinase 2 biomarkers and uses thereof |
| WO2020168197A1 (en) | 2019-02-15 | 2020-08-20 | Incyte Corporation | Pyrrolo[2,3-d]pyrimidinone compounds as cdk2 inhibitors |
| TW202100520A (zh) | 2019-03-05 | 2021-01-01 | 美商英塞特公司 | 作為cdk2 抑制劑之吡唑基嘧啶基胺化合物 |
| US11628162B2 (en) | 2019-03-08 | 2023-04-18 | Incyte Corporation | Methods of treating cancer with an FGFR inhibitor |
| US11919904B2 (en) | 2019-03-29 | 2024-03-05 | Incyte Corporation | Sulfonylamide compounds as CDK2 inhibitors |
| US11447494B2 (en) | 2019-05-01 | 2022-09-20 | Incyte Corporation | Tricyclic amine compounds as CDK2 inhibitors |
| US11440914B2 (en) | 2019-05-01 | 2022-09-13 | Incyte Corporation | Tricyclic amine compounds as CDK2 inhibitors |
| US11591329B2 (en) | 2019-07-09 | 2023-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| CA3148776A1 (en) | 2019-08-01 | 2021-02-04 | Incyte Corporation | A dosing regimen for an ido inhibitor |
| MX2022001940A (es) | 2019-08-14 | 2022-05-10 | Incyte Corp | Compuestos de imidazolil pirimidinilamina como inhibidores de cdk2. |
| PE20221905A1 (es) | 2019-10-11 | 2022-12-23 | Incyte Corp | Aminas biciclicas como inhibidoras de la cdk2 |
| IL291901A (en) | 2019-10-14 | 2022-06-01 | Incyte Corp | Bicyclyl heterocycles as fgr suppressors |
| WO2021076728A1 (en) | 2019-10-16 | 2021-04-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| WO2021113479A1 (en) | 2019-12-04 | 2021-06-10 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| KR20220131900A (ko) | 2019-12-04 | 2022-09-29 | 인사이트 코포레이션 | Fgfr 억제제의 유도체 |
| JP2023516441A (ja) | 2020-03-06 | 2023-04-19 | インサイト・コーポレイション | Ａｘｌ／ｍｅｒ阻害剤及びｐｄ－１／ｐｄ－ｌ１阻害剤を含む併用療法 |
| JP2021167301A (ja) | 2020-04-08 | 2021-10-21 | ファイザー・インク | Ｃｄｋ２阻害剤に対する腫瘍適応を抑制するためのｃｄｋ４／６およびｃｄｋ２阻害剤による同時処置 |
| IL297165A (en) | 2020-04-16 | 2022-12-01 | Incyte Corp | Soysag tricyclic CRS inhibitors |
| WO2021231526A1 (en) | 2020-05-13 | 2021-11-18 | Incyte Corporation | Fused pyrimidine compounds as kras inhibitors |
| WO2021236650A1 (en) | 2020-05-19 | 2021-11-25 | G1 Therapeutics, Inc. | Cyclin-dependent kinase inhibiting compounds for the treatment of medical disorders |
| US10988479B1 (en) | 2020-06-15 | 2021-04-27 | G1 Therapeutics, Inc. | Morphic forms of trilaciclib and methods of manufacture thereof |
| TW202214650A (zh) | 2020-06-15 | 2022-04-16 | 美商G1治療公司 | 曲拉西利(trilaciclib)之型態形式及製造方法 |
| WO2022047093A1 (en) | 2020-08-28 | 2022-03-03 | Incyte Corporation | Vinyl imidazole compounds as inhibitors of kras |
| US11767320B2 (en) | 2020-10-02 | 2023-09-26 | Incyte Corporation | Bicyclic dione compounds as inhibitors of KRAS |
| US20230374028A1 (en) * | 2020-10-08 | 2023-11-23 | Teva Pharmaceuticals International Gmbh | Solid state forms of trilaciclib and of trilaciclib salts |
| WO2022155941A1 (en) | 2021-01-25 | 2022-07-28 | Qilu Regor Therapeutics Inc. | Cdk2 inhibitors |
| WO2022206888A1 (en) | 2021-03-31 | 2022-10-06 | Qilu Regor Therapeutics Inc. | Cdk2 inhibitors and use thereof |
| JP2024513575A (ja) | 2021-04-12 | 2024-03-26 | インサイト・コーポレイション | Ｆｇｆｒ阻害剤及びネクチン－４標的化剤を含む併用療法 |
| AR126102A1 (es) | 2021-06-09 | 2023-09-13 | Incyte Corp | Heterociclos tricíclicos como inhibidores de fgfr |
| US20230002384A1 (en) | 2021-06-09 | 2023-01-05 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| KR20240032915A (ko) | 2021-07-07 | 2024-03-12 | 인사이트 코포레이션 | Kras의 저해제로서의 삼환식 화합물 |
| CA3224841A1 (en) | 2021-07-14 | 2023-01-19 | Zhenwu Li | Tricyclic compounds as inhibitors of kras |
| AU2022320615A1 (en) | 2021-07-26 | 2024-03-14 | Celcuity Inc. | 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea (gedatolisib) and its combinations for use in the treatment of cancer |
| CN113788837B (zh) * | 2021-08-02 | 2022-08-26 | 深圳湾实验室坪山生物医药研发转化中心 | Trilaciclib的合成方法 |
| US20230174555A1 (en) | 2021-08-31 | 2023-06-08 | Incyte Corporation | Naphthyridine compounds as inhibitors of kras |
| WO2023049697A1 (en) | 2021-09-21 | 2023-03-30 | Incyte Corporation | Hetero-tricyclic compounds as inhibitors of kras |
| US20230143938A1 (en) | 2021-10-01 | 2023-05-11 | Incyte Corporation | Pyrazoloquinoline kras inhibitors |
| AU2022367432A1 (en) | 2021-10-14 | 2024-05-02 | Incyte Corporation | Quinoline compounds as inhibitors of kras |
| TW202320792A (zh) | 2021-11-22 | 2023-06-01 | 美商英塞特公司 | 包含ｆｇｆｒ抑制劑及ｋｒａｓ抑制劑之組合療法 |
| TW202329937A (zh) | 2021-12-03 | 2023-08-01 | 美商英塞特公司 | 雙環胺ｃｋ１２抑制劑 |
| US20230183251A1 (en) | 2021-12-10 | 2023-06-15 | Incyte Corporation | Bicyclic amines as cdk12 inhibitors |
| US11976073B2 (en) | 2021-12-10 | 2024-05-07 | Incyte Corporation | Bicyclic amines as CDK2 inhibitors |
| US20230192722A1 (en) | 2021-12-22 | 2023-06-22 | Incyte Corporation | Salts and solid forms of an fgfr inhibitor and processes of preparing thereof |
| TW202341982A (zh) | 2021-12-24 | 2023-11-01 | 大陸商上海齊魯銳格醫藥研發有限公司 | Ｃｄｋ２抑制劑及其用途 |
| WO2023168686A1 (en) | 2022-03-11 | 2023-09-14 | Qilu Regor Therapeutics Inc. | Substituted cyclopentanes as cdk2 inhibitors |
| WO2023164255A1 (en) | 2022-02-28 | 2023-08-31 | Teva Pharmaceuticals International Gmbh | Crystalline forms of trilaciclib and trilaciclib salts |
| US20230279004A1 (en) | 2022-03-07 | 2023-09-07 | Incyte Corporation | Solid forms, salts, and processes of preparation of a cdk2 inhibitor |
| WO2023250430A1 (en) | 2022-06-22 | 2023-12-28 | Incyte Corporation | Bicyclic amine cdk12 inhibitors |
| WO2024015731A1 (en) | 2022-07-11 | 2024-01-18 | Incyte Corporation | Fused tricyclic compounds as inhibitors of kras g12v mutants |
| CN115536663A (zh) * | 2022-10-11 | 2022-12-30 | 杭州科巢生物科技有限公司 | 一种曲拉西利中间体及其制备与应用 |
| CN117069663B (zh) * | 2023-08-31 | 2023-12-26 | 四川维亚本苑生物科技有限公司 | 一种瑞博西尼中间体v的合成方法及瑞博西尼的合成方法 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK0552237T3 (da) * | 1990-10-09 | 1993-07-28 | Neurogen Corp | Visse cycloalkyl- og azacycloalkyl-pyrrolopyrimidiner, en klasse af ligander for GABA-receptorer i hjernen |
| GB9718913D0 (en) | 1997-09-05 | 1997-11-12 | Glaxo Group Ltd | Substituted oxindole derivatives |
| EA012926B1 (ru) * | 2001-12-20 | 2010-02-26 | Оси Фармасьютикалз, Инк. | Пирролопиримидиновые соединения, относящиеся к a-селективным антагонистам, их синтез и применение |
| ATE314370T1 (de) | 2002-01-22 | 2006-01-15 | Warner Lambert Co | 2-(pyridin-2-ylamino)-pyrido(2,3-d)pyrimidin-7- one |
| MXPA04008680A (es) * | 2002-02-19 | 2004-12-06 | Pharmacia Italia Spa | Derivados de pirazol triciclicos, procedimientos para su preparacion y su uso como agentes anti-tumorales. |
| JP2006516561A (ja) | 2003-01-17 | 2006-07-06 | ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー | 細胞増殖の阻害剤としての２−アミノピリジン置換ヘテロ環類 |
| GEP20094664B (en) * | 2003-05-22 | 2009-04-10 | Nerviano Medical Sciences Srl | Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors |
| WO2005040166A1 (en) | 2003-10-23 | 2005-05-06 | F.Hoffmann-La Roche Ag | Triaza-spiropiperidine derivatives for use as glyt-1 inhibitors in the treatment of neurological and neuropsychiatric disorders |
| GB0327380D0 (en) * | 2003-11-25 | 2003-12-31 | Cyclacel Ltd | Method |
| ITMI20040874A1 (it) | 2004-04-30 | 2004-07-30 | Ist Naz Stud Cura Dei Tumori | Derivati indolici ed azaindolici con azione antitumorale |
| EP1779848A1 (en) | 2005-10-28 | 2007-05-02 | Nikem Research S.R.L. | V-ATPase inhibitors for the treatment of inflammatory and autoimmune diseases |
| TWI398252B (zh) * | 2006-05-26 | 2013-06-11 | Novartis Ag | 吡咯并嘧啶化合物及其用途 |
| ES2527696T3 (es) * | 2006-12-21 | 2015-01-28 | Nerviano Medical Sciences S.R.L. | Derivados de pirazoloquinazolina sustituidos, procedimientos para su preparación y su uso como inhibidores de la quinasa |
| BRPI0813647A2 (pt) | 2007-06-25 | 2014-12-23 | Neurogen Corp | Piperazinil oxoalquil tetrahidro-beta-carbolinas e análogos relacionados |
| WO2009085185A1 (en) * | 2007-12-19 | 2009-07-09 | Amgen Inc. | Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors |
| PL2331547T3 (pl) * | 2008-08-22 | 2015-01-30 | Novartis Ag | Związki pirolopirymidynowe jako inhibitory CDK |
| AU2009310352A1 (en) | 2008-10-01 | 2010-05-06 | The University Of North Carolina At Chapel Hill | Hematopoietic protection against ionizing radiation using selective cyclin-dependent kinase 4/6 inhibitors |
| AU2009298367A1 (en) | 2008-10-01 | 2010-04-08 | The University Of North Carolina At Chapel Hill | Hematopoietic protection against chemotherapeutic compounds using selective cyclin-dependent kinase 4/6 inhibitors |
| CN102458443A (zh) | 2009-05-13 | 2012-05-16 | 北卡罗来纳大学查珀尔希尔分校 | 细胞周期蛋白依赖性激酶抑制剂及使用方法 |
| WO2011103485A1 (en) | 2010-02-18 | 2011-08-25 | Medivation Technologies, Inc. | Fused tetracyclic pyrido[4,3-b]indole and pyrido[3,4-b]indole derivatives and methods of use |
| EP3216792B1 (en) * | 2012-03-29 | 2020-05-27 | G1 Therapeutics, Inc. | Lactam kinase inhibitors |
-
2011
- 2011-10-25 JP JP2013535153A patent/JP5923509B2/ja active Active
- 2011-10-25 EP EP21184036.8A patent/EP3981770A1/en not_active Withdrawn
- 2011-10-25 AU AU2011323739A patent/AU2011323739B2/en active Active
- 2011-10-25 KR KR1020207034378A patent/KR20200137048A/ko not_active Application Discontinuation
- 2011-10-25 RS RS20160734A patent/RS55135B1/sr unknown
- 2011-10-25 DK DK11838545.9T patent/DK2632467T3/en active
- 2011-10-25 MX MX2016004581A patent/MX367795B/es unknown
- 2011-10-25 CN CN201410184794.1A patent/CN104045654A/zh active Pending
- 2011-10-25 RU RU2013123790A patent/RU2621674C2/ru active
- 2011-10-25 CN CN201180062297.9A patent/CN103429243B/zh active Active
- 2011-10-25 SI SI201130943A patent/SI2632467T1/sl unknown
- 2011-10-25 EP EP18167945.7A patent/EP3381920B1/en active Active
- 2011-10-25 KR KR1020197035200A patent/KR102186969B1/ko active IP Right Grant
- 2011-10-25 CN CN201410184792.2A patent/CN103936745B/zh active Active
- 2011-10-25 ES ES11838545.9T patent/ES2592515T3/es active Active
- 2011-10-25 CN CN201610323241.9A patent/CN106008533B/zh active Active
- 2011-10-25 PT PT118385459T patent/PT2632467T/pt unknown
- 2011-10-25 CA CA2961937A patent/CA2961937C/en active Active
- 2011-10-25 SG SG10201508715YA patent/SG10201508715YA/en unknown
- 2011-10-25 MX MX2013004681A patent/MX338327B/es active IP Right Grant
- 2011-10-25 EP EP19164126.5A patent/EP3567042B1/en active Active
- 2011-10-25 PL PL11838545.9T patent/PL2632467T3/pl unknown
- 2011-10-25 EP EP15170738.7A patent/EP2955183A1/en not_active Withdrawn
- 2011-10-25 KR KR1020187035510A patent/KR102051881B1/ko active IP Right Grant
- 2011-10-25 CN CN201611022263.8A patent/CN106967074A/zh active Pending
- 2011-10-25 KR KR1020137013388A patent/KR101929593B1/ko active IP Right Grant
- 2011-10-25 CA CA2815084A patent/CA2815084C/en active Active
- 2011-10-25 EP EP11838545.9A patent/EP2632467B1/en active Active
- 2011-10-25 SG SG2013031554A patent/SG189525A1/en unknown
- 2011-10-25 MX MX2020005498A patent/MX2020005498A/es unknown
- 2011-10-25 LT LTEP11838545.9T patent/LT2632467T/lt unknown
- 2011-10-25 WO PCT/US2011/057749 patent/WO2012061156A1/en active Application Filing
- 2011-10-25 BR BR112013010018-4A patent/BR112013010018B1/pt active IP Right Grant
- 2011-10-25 HU HUE11838545A patent/HUE030714T2/en unknown
- 2011-10-25 EP EP16168485.7A patent/EP3118203B1/en active Active
-
2013
- 2013-04-24 US US13/869,576 patent/US8598197B2/en active Active
- 2013-04-24 US US13/869,520 patent/US8598186B2/en active Active
- 2013-04-25 IL IL225940A patent/IL225940A0/en unknown
- 2013-04-25 MX MX2019010602A patent/MX2019010602A/es unknown
-
2014
- 2014-10-23 HK HK14110598A patent/HK1197067A1/xx unknown
-
2015
- 2015-03-05 IL IL237582A patent/IL237582A0/en unknown
- 2015-03-05 IL IL237581A patent/IL237581B/en active IP Right Grant
-
2016
- 2016-04-15 JP JP2016082206A patent/JP6157680B2/ja active Active
- 2016-07-13 AU AU2016204879A patent/AU2016204879B2/en active Active
- 2016-08-26 HR HRP20161092TT patent/HRP20161092T1/hr unknown
- 2016-09-09 SM SM201600311T patent/SMT201600311B/it unknown
- 2016-09-13 CY CY20161100906T patent/CY1118004T1/el unknown
-
2017
- 2017-05-04 IL IL252108A patent/IL252108B/en active IP Right Grant
- 2017-06-02 JP JP2017110115A patent/JP6389926B2/ja active Active
-
2018
- 2018-04-30 AU AU2018202991A patent/AU2018202991B2/en active Active
- 2018-08-17 JP JP2018153563A patent/JP2018193400A/ja not_active Ceased
- 2018-10-18 HK HK18113421.2A patent/HK1254345B/zh unknown
-
2020
- 2020-01-12 IL IL271977A patent/IL271977B/en active IP Right Grant
- 2020-05-07 AU AU2020203035A patent/AU2020203035B2/en active Active
- 2020-05-07 AU AU2020203037A patent/AU2020203037B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SMT201600311B (it) | Inibitori di cdk | |
| SMT201500271B (it) | Inibitori di neprilisina | |
| SMT201600141B (it) | Boronati quali inibitori di arginasi | |
| DK3590934T3 (da) | Pyrazolylquinoxalinkinasehæmmere | |
| SMT201600114B (it) | Inibitori di beta-secretasi | |
| CO6970602A2 (es) | Inhibidores de quinasa | |
| DK2371923T3 (da) | Aflejringshæmmer | |
| BR112013016154A2 (pt) | inibidores de faah | |
| DK2710007T3 (da) | Kinasehæmmere | |
| BR112012028556A2 (pt) | Indóis | |
| CR20130111A (es) | Triazina-oxidiazoles | |
| DE10170954T8 (de) | Mikrowellendruckgarer | |
| DK2466065T3 (da) | Brøndkomplettering | |
| CU24164B1 (es) | Inhibidores sustituidos de acetil-coa carboxilasa | |
| BR112013025761A2 (pt) | inibidores de hsp90 | |
| DE102011002623A8 (de) | Ventilsteuerzeitversteller | |
| DE102010019119B8 (de) | Cuttermesser | |
| BR112013014148A2 (pt) | inibidores de corrosão | |
| FR2959228B1 (fr) | Nucleotides modifies | |
| DE102010038420A8 (de) | Reinigungungsvorrichtung | |
| BR112013014484A2 (pt) | compostos inibidores de metaloenzimas | |
| DE102010035554B8 (de) | Fußtüröffner | |
| DK2652241T3 (da) | Brøndkomplettering | |
| BR112013014731A2 (pt) | tamavidina modificada | |
| BR112013012958A2 (pt) | inibidores integrin ligado com quinase |